Modern drug discovery and development start with the discovery of an essential, disease-related target, understanding its role from a cell biology perspective, and the search for compounds that specifically interfere with function of this target. Often a first step is the screening of large, diverse, compound libraries — high-throughput screening (HTS) — including rapid characterization of hits as a high priority.

Unlike other current large-scale HTS systems, LamdaGen’s platform can not only provide qualitative feedback on compound-target interaction without requiring labels, but also will supply valuable information regarding a compound’s binding affinity (KD) to its target as a function of measured rate constants for association (ka) and dissociation (kd).

Lamdagen’s technology allows the detection and characterization of molecular events such as receptor—ligand and protein— ligand interactions in both simple and complex matrices without having to rely on labels in assay development. This huge advantage will become increasingly important as the number of poorly characterized targets increases based on advancements in functional genomics and proteomics.

Antibody / Antigen

Monoclonal and TNFα antibodies binding to TNFα

Tumor Necrosis Factor alpha (TNFα) is a cytokine whose primary role is in the regulation of immune cells. TNF is involved in many cellular processes such as apoptosis, cellular proliferation, differentiation, inflammation, tumorigenesis and viral replication.

Dysfunction, in particular overproduction of TNF, has been linked to a variety of human diseases and in cancer. It is therefore a molecule of interest of the development of drugs and an ideal model system for our technology.

A. Binding is specific

B. Two different monoclonal anti-human TNF antibodies bind to different epitopes